Study on the Level of Information on the Risks Related to Tobacco of Persons Consulting in Psychiatry and on Access to Aids in Case of Smoking, Comparing With Persons Consulting in Diabetology or in Addictology

August 4, 2021 updated by: Dr Nadia YOUNES, Versailles Hospital

INFO-AIDE-TABAC Study on the Level of Information on the Risks Related to Tobacco of Persons Consulting in Psychiatry and on Access to Aids in Case of Smoking, Comparing With Persons Consulting in Diabetology or in Addictology

this is an observational study that involves providing a questionnaire to patients consulting in psychiatry, addictology (other than tobacco) and endocrinology to assess their knowledge of tobacco risks and access to smoking cessation aids

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

310

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Le Chesnay, France, 78150
        • Centre Hospitalier de Versailles
      • Paris, France
        • Hôpital Ferdinand Widal

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients who come at :

  • Department of Psychiatry for Adults of the Hospital of Versailles of Dr N Bazin (André Mignot in Chesnay): CMP (Centre Médico-psychologique), HDJ (Day Hospital).
  • Endocrinology service of Dr JP Beressi of the Hospital of Versailles (André Mignot in Chesnay): consultation, HDJ
  • Addictology service CSAPA (Espace Murger) by Dr F Vorspan of the Fernand-Widal Hospital in Paris

Description

Inclusion Criteria:

  • Patients > 18 years
  • Men and women
  • who comes for consultation during the study
  • Psychiatry on CMP or HDJ, regardless of diagnosis or smoking status
  • Endocrinology in consultation or HDJ
  • In addictology at CSAPA

Exclusion Criteria:

  • Patient unable to complete questionnaire (not speaking French, confused, alcoholics, etc.)
  • Refusal to complete questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Psychiatry
patients who come for psychiatric consultation
Tobacco Use and Risk Questionnaire
addictology (other than tabacco)
patients who come for addictology consultation
Tobacco Use and Risk Questionnaire
endocrinology
patients who come for endocrinology consultation
Tobacco Use and Risk Questionnaire

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
to Assess the level of information on tobacco-related risks of patients with questionnaire
Time Frame: at the end of study, average 2 month
to Assess the level of information on tobacco-related risks of patients monitored for psychiatric disorders by comparing them to patients monitored for an addiction other than tobacco or to patients monitored for a chronic disease
at the end of study, average 2 month
to Assess access to smoking cessation aids for smokers and ex-smokers with questionnaire
Time Frame: at the end of study, average 2 month
to Assess access to smoking cessation aids for smokers and ex-smokers among psychiatric patients compared to smokers and ex-smokers among patients who have been monitored for an addiction other than tobacco or among patients who have been monitored for a chronic disease (endocrine).
at the end of study, average 2 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 12, 2019

Primary Completion (Actual)

June 30, 2020

Study Completion (Actual)

December 31, 2020

Study Registration Dates

First Submitted

February 28, 2020

First Submitted That Met QC Criteria

April 2, 2020

First Posted (Actual)

April 3, 2020

Study Record Updates

Last Update Posted (Actual)

August 5, 2021

Last Update Submitted That Met QC Criteria

August 4, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • P19/12_info_aide_tabac

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Consumption, Tobacco

Clinical Trials on questionnaire

3
Subscribe